联合王国提议进行医药价格改革,以提高透明度和加强问责制。 UK proposes medicine pricing reforms to boost transparency and accountability.

联合王国政府正在就拟议更新药品定价和透明度条例问题进行磋商,目的是使法定制度与自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿自愿协定保持一致,改进数据披露工作,并加强整个医药供应链的问责制。 The UK government is consulting on proposed updates to medicines pricing and transparency regulations, aiming to align the statutory scheme with the voluntary VPAG agreement, improve data disclosure, and enhance accountability across the pharmaceutical supply chain. 这些改变是2022年以来对条例进行更广泛审查的一部分,力求确保及时、准确的信息共享,支持公平定价,并保持获得创新治疗的机会。 The changes, part of a broader review of regulations since 2022, seek to ensure timely, accurate information sharing, support fair pricing, and maintain access to innovative treatments. 请包括工业和保健团体在内的利益攸关方就拟议的改革提供反馈意见,以加强保健系统的透明度和公众对保健系统的信任。 Stakeholders, including industry and healthcare groups, are invited to provide feedback on the proposed reforms to strengthen transparency and public trust in the health system.